Meloxicam Solubility via SBEβCD Inclusion Complex
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Meloxicam, a nonsteroidal anti-inflammatory drug, has poor aqueous solubility, leading to reduced bioavailability and delayed pain relief, necessitating a method to enhance its solubility and absorption.
Innovation Solution
A dosage form combining meloxicam with sulfobutyl ether β-cyclodextrin (SBEβCD) and a bicarbonate, forming an inclusion complex to increase solubility and bioavailability, and when administered with rizatriptan, provides rapid and sustained pain relief for migraine treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If meloxicam is used alone, then it provides anti-inflammatory and analgesic effects, but its poor aqueous solubility reduces bioavailability and delays pain relief
Solution Approach 1:
The patent employs cyclodextrins as intermediary carriers that form inclusion complexes with meloxicam. The cyclodextrin structure contains a hydrophobic cavity that accommodates the meloxicam molecule, while the hydrophilic exterior enhances aqueous solubility. This mediator approach resolves the solubility-bioavailability contradiction without altering the meloxicam molecule itself.
Solution Approach 2:
The patent creates a composite pharmaceutical system combining meloxicam with cyclodextrin derivatives (such as sulfobutyl ether β-cyclodextrin). This composite material integrates the therapeutic properties of meloxicam with the solubility-enhancing characteristics of cyclodextrin, achieving both anti-inflammatory efficacy and improved bioavailability.
2Speed
If meloxicam is administered alone, then it provides pain relief, but the onset of pain relief is slow due to poor solubility
Solution Approach 1:
Cyclodextrin serves as a mediator that facilitates rapid dissolution and absorption of meloxicam. The inclusion complex structure allows the drug to be released quickly in the gastrointestinal tract, accelerating the onset of pain relief while maintaining the therapeutic effectiveness of meloxicam.
3Reliability
If a combination of meloxicam with SBEβCD and bicarbonate is used, then bioavailability and absorption are significantly enhanced, but the dosage form complexity increases
Solution Approach 1:
The patent merges multiple functional components (meloxicam, SBEβCD, and bicarbonate) into a single integrated dosage form. The bicarbonate component addresses gastric irritation while the SBEβCD-enhanced meloxicam provides improved solubility and absorption. This combination approach consolidates multiple therapeutic benefits into one administration unit.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination significantly enhances meloxicam's bioavailability and absorption, leading to rapid and sustained pain relief in migraine patients, reducing the need for rescue medication and improving treatment outcomes compared to meloxicam or rizatriptan alone.
Implementation Method 1
In aqueous solutions, cyclodextrins can form complexes (i.e., an inclusion complex) with drugs by incorporating the drug into the center/hydrophobic portion of the cyclodextrin ring
Implementation Method 2
Cyclodextrins are hydrophobic on the inside and hydrophilic on the inside which helps to facilitate the transport of molecules
Data Source
AI summary
Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.